News and Press Releases

Samsung Bioepis Begins Commercialization of BYOOVIZ, Biosimilar to Lucentis (Ranibizumab), in Europe

Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ BYOOVIZ becomes the fourth biosimilar directly commercialized by Samsung Bioepis in Europe, following EPYSQLI...

Category: Logistics, Other, Pharmaceutical
Posted: January 2, 2026

MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics

23 December 2025 -- Geneva, Switzerland -- MindMaze Therapeutics Holding SA, a commercial-stage company delivering evidence-based, precision digital treatments for neurological diseases, today outlined the evolution of its global reimbursement...

Category: Logistics, Other, Pharmaceutical
Posted: December 23, 2025

Chemin de Roseneck 5 1006 Lausanne, Switzerland

Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients

Brainomix 360 Stroke imaging was utilized to improve and standardize the grading of baseline stroke severity, prior to treatment in patients enrolled in Argenica Therapeutic’s Phase II study of neuroprotective...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 18, 2025

First Floor, Seacourt Tower West Way Oxford OX2 0JJ

New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations

Both monthly maintenance doses (100 mg and 300 mg) improved opioid abstinence and were well-tolerated with no new safety signals identified Post-hoc analyses indicated the 300-mg monthly maintenance dose performed...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 17, 2025

North Chesterfield, Virginia, USA

Leucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell Engineering

Enables in vivo delivery of LEU011 harnessing the VivoCell Platform 15 December 2025 -- London, UK and Illinois, US -- Leucid Bio, a privately-held biotechnology company developing innovative Chimeric Antigen Receptor...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 15, 2025

3rd Floor, Bermondsey Wing Guy's Hospital London SE1 9RT

Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics

15 December 2025 -- Geneva, Switzerland -- MindMaze Therapeutics Holding SA announced today the completion of its business combination with NeuroX Group SA (NeuroX), a commercial-stage company delivering evidence-based, precision...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 15, 2025

Chemin de Roseneck 5 1006 Lausanne, Switzerland

Gaelic Labs’ acquisition of Athlone boosts Gaelic’s leadership in the Beta Lactam industry

11 December 2025 -- Tipperary, Ireland -- Gaelic Laboratories, a world-class manufacturer of Beta-Lactam (penicillin) products, today announces its acquisition of Athlone Laboratories, a leading developer and manufacturer of oral...

Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: December 11, 2025

Old Waterford Rd, Gurtnafleur, Clonmel, Co. Tipperary, E91 CD92 Ireland

FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial

FDA has completed their review of the Neurizon NUZ-001 regimen to the HEALEY ALS Platform Trial Master Protocol This marks the official entry of NUZ-001 as Regimen I in the...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 11, 2025

Level 4, 96-100 Albert Road South Melbourne, VIC 3205 Australia

ProteoNic 2G UNic Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies

11 December 2025 -- Leiden, The Netherlands -- ProteoNic BV, a leading provider of premium vector technology for biopharmaceutical and viral vector production, today announced that its proprietary 2G UNic® technology...

Category: BioManufacturing, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 11, 2025

J.H. Oortweg 19-21 – 2333 CH Leiden – The Netherlands

Medable Launches Innovation Evidence Workshop – First Collaboration To Bring Leaders Together on DCT Impact, Adoption, and Best Practices

PALO ALTO, California – December 10, 2025 – Medable, the leading provider of AI-powered clinical trial technology, today announced its Innovation Evidence Workshop series, developed in collaboration with and facilitated...

Category:
Posted: December 10, 2025

525 University Ave Suite A70 Palo Alto, CA 94301

Fibrocor Therapeutics appoints world-leading nephrologists to Clinical Advisory Board with a focus on its lead indication Alport Syndrome

Fibrocor Therapeutics strengthens its clinical strategy with the appointment of four world-leading nephrology and genetics experts to its Clinical Advisory Board (CAB), reinforcing its scientific leadership in Alport Syndrome The...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: December 9, 2025

661 University Ave, Suite 1300 Toronto, Ontario Canada M5G 0B7

Phillips Medisize Highlights Inhaled Drug Delivery Device Platforms and Scientific Insights at DDL 2025

HUDSON, WI (9 December 2025) Phillips Medisize, a Molex company and a leader in the design, development, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices,...

Category:
Posted: December 9, 2025

Edisonstraat 1 Hillegom 2181 AB

Cold Chain Technologies Expands Industry-Leading Reusable Portfolio

Cold Chain Technologies has announced the launch of the EcoFlex 3, an evolution of its shape stable, full-coverage PCM family of EcoFlex reusable shippers. The range, known for its high-performance...

Category:
Posted: December 9, 2025

29 Everett Street, Holliston, MA 01746

Astellas To Present New Data on XOSPATA (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting

Presentations include pooled post-hoc analysis of the Phase 3 ADMIRAL and COMMODORE data on post-transplant gilteritinib resumption in relapsed or refractory FLT3m+ AML Findings from the Phase 3 MORPHO trial...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 5, 2025

2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, Japan

Micro Systems at Drug Delivery to the Lungs Conference 2025

Micro Systems, now part of VANGEST Group, will participate in the DDL Co​nference, the foremost international event dedicated to pulmonary and nasal drug delivery. VANGEST brings specialised expertise in ultra-precision inhalation...

Category:
Posted: December 5, 2025

Golborne Enterprise Park, Golborne, Warrington WA3 3GR